Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 84

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 2
Chunk 84
---

    2024 
  
    Net cash and cash equivalents (used in) provided by: 

    Operating activities 
    $(14,199) 
    $(15,362)
  
    Investing activities 
     (706) 
     - 
  
    Financing activities 
     27,545  
     10,497 
  
    Change in cash and cash equivalents 
     12,640  
     (4,865)
  
    Impact on cash from foreign currency translation 
     (188) 
     86 
  
    Cash and cash equivalents, beginning of period 
     20,922  
     35,848 
  
    Cash and cash equivalents, end of period 
    $33,374  
    $31,069 

Operating Activities 

Operating activities used approximately $14.2 million of cash during
the six months ended June 30, 2025, resulting mainly from our loss of $34.2 million, partially offset by an intangibles impairment expense
of $16.5 million and non-cash stock-based compensation of $3.6 million.

Operating activities used
approximately $15.4 million of cash during the six months ended June 30, 2024, resulting from our loss of $20.8 million, partially offset
by changes in our net operating assets and liabilities of $1.2 million and non-cash stock-based compensation of $4.1 million. The change
in our net operating assets and liabilities was mainly due to an increase in accounts payable and accrued liabilities of $1.4 million,
a decrease in prepaid expenses of $0.5 million and a decrease in other tax receivable of $0.3 million, partially offset by an increase
in research and development tax receivable of $1.2 million.

Investing Activities

During the six months ended
June 30, 2025, the Company acquired $0.7 million of equipment to be used in its CORDStrom clinical program.

Financing Activities

During the six months ended
June 30, 2025, the Company sold 1,304,707 shares of common stock under its ATM program for net proceeds of $10.1 million.

During June 2025, the Company
sold 3,000,000 shares of its common stock in a registered direct offering in exchange for gross proceeds of $18.9 million (net proceeds
of $17.4 million).

During